Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk

Nephrology

Volumn 17, Issue 5, 2012, Pages 433-444

  Toussaint, Nigel D ^a,b,c   Pedagogos, Eugenie ^a   Tan, Sven Jean ^a,c   Badve, Sunil V ^d   Hawley, Carmel M ^d   Perkovic, Vlado ^e   Elder, Grahame J ^f,g  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b WESTERN HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

bone metabolism; cardiovascular risk; chronic kidney disease (CKD); phosphate

Indexed keywords

CALCIUM; CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM; PARATHYROID HORMONE; PHOSPHATE; REACTIVE OXYGEN METABOLITE; SEVELAMER;

AGING; ANGINA PECTORIS; ARTERIAL STIFFNESS; BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; DIABETES MELLITUS; DIET THERAPY; DISEASE CONTROL; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HORMONE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERPHOSPHATASEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; METABOLIC DISORDER; MINERAL AND BONE DISORDER; MINERAL METABOLISM; MORBIDITY; MORTALITY; NEPHRON; OUTCOME ASSESSMENT; PATIENT COUNSELING; PERIPHERAL VASCULAR DISEASE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; STROKE;

BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY DISEASES; PHOSPHATES; PHOSPHORUS, DIETARY; RISK ASSESSMENT; RISK FACTORS; VASCULAR CALCIFICATION; VASCULAR STIFFNESS;

EID: 84863008935     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01618.x     Document Type: Review

References (127)

1. Tonelli M, Sacks F, Pfeffer M, et al,. Relationship between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-33. (Pubitemid 41532599)
2. Kestenbaum B, Sampson JN, Rudser KD, et al,. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-8. (Pubitemid 41725150)
3. Dhingra R, Sullivan L, Fox S, et al,. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Int. Med. 2007; 167: 879-85. (Pubitemid 46762749)
4. Block G, Hulbert-Shearon T, et al,. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 1998; 31: 607-17.
5. Palmer SC, Hayen A, Macaskill P, et al,. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 2011; 305: 1119-27.
6. O'Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS,. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol. Dial. Transplant. 2011; 26: 2885-90.
7. Berndt T, Kumar R,. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 2007; 69: 341-59. (Pubitemid 46457647)
8. Levin A, Bakris GL, Molitch M, et al,. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-8. (Pubitemid 44967731)
9. Cunningham J, Locatelli F, Rodriguez M,. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2011; 6: 913-21.
10. Weiner DE, Tighiouart H, Amin MG, et al,. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004; 15: 1307-15. (Pubitemid 38526012)
11. Foley RN, Parfrey PS, Sarnak MJ,. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112-19. (Pubitemid 28527268)
12. Go AS, Chertow GM, Fan D, et al,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
13. Chronic Kidney Disease Prognosis Consortium;, Matsushita K, van der Velde M, Astor BC, et al,. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-81.
14. Muntner P, He J, Astor BC, et al,. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 2005; 16: 529-38. (Pubitemid 41725151)
15. Eddington H, Hoefield R, Sinha S, et al,. Serum phosphate and mortality in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 2251-7.
16. Moe SM, Drueke T, Lameire N, et al,. Chronic kidney disease-mineral and bone disorder: A new paradigm. Adv. Chronic Kidney Dis. 2007; 14: 3-12. (Pubitemid 46014534)
17. Dhingra R, Gona P, Benjamin EJ, et al,. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur. J. Heart. Fail. 2010; 12: 812-18.
18. Foley RN, Collins AJ, Herzog CA, et al,. Serum phosphate and left ventricular hypertrophy in young adults: The coronary artery risk development in young adults study. Kidney Blood Press. Res. 2009; 32: 37-44.
19. Foley RN, Collins AJ, Herzog CA, et al,. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J. Am. Soc. Nephrol. 2009; 20: 397-404.
20. Ix JH, De Boer IH, Peralta CA, et al,. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin. J. Am. Soc. Nephrol. 2009; 4: 609-15.
21. Adeney KL, Siscovick DS, Ix JH, et al,. Association of serum phosphate with vascular and valvular calcification in moderate ckd. J. Am. Soc. Nephrol. 2009; 20: 381-7.
22. Chue CD, Edwards NC, Moody WE, et al,. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart 2012; 98: 219-24.
23. Chue CD, Edwards NC, Davis LJ, Steeds RP, Townend JN, Ferro CJ,. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol. Dial. Transplant. 2011; 26: 2576-82.
24. Landray MJ, Emberson JR, Blackwell L, et al,. Prediction of ESRD and death among people with CKD: The Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am. J. Kidney Dis. 2010; 56: 1082-94.
25. Connolly GM, Cunningham R, McNamee PT, et al,. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 2009; 87: 1040-44.
26. Moore J, Tomson CR, Tessa Savage M, Borrows R, Ferro CJ,. Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clin. Transplant. 2011; 25: 406-16.
27. Schaeffner ES, Födinger M, Kramar R, Sunder-Plassmann G, Winkelmayer WC,. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl. Int. 2007; 20: 247-55.
28. Benavente D, Chue CD, Moore J, Addison C, Borrows R, Ferro CJ,. Serum phosphate measured at 6 and 12 months after successful kidney transplant is independently associated with subsequent graft loss. Exp. Clin. Transplant. 2012; 10: 119-24.
29. Jung HH, Kim S-W, Han H,. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol. Dial. Transplant. 2006; 21: 1915-20. (Pubitemid 43985720)
30. Toussaint ND, Lau KK, Strauss BJ, et al,. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol. Dial. Transplant. 2008; 23: 586-93. (Pubitemid 351767633)
31. Shuto E, Taketani Y, Tanaka R, et al,. Dietary phosphorus acutely impairs endothelial function. J. Am. Soc. Nephrol. 2009; 20: 1504-12.
32. Giachelli CM,. The emerging role of phosphate in vascular calcification. Kidney Int. 2009; 75: 890-7.
33. Amann K, Tornig J, Kugel B, et al,. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003; 63: 1296-301. (Pubitemid 36349995)
34. Chue CD, Townend JN, Steeds RP, Ferro CJ,. Arterial stiffness in chronic kidney disease: Causes and consequences. Heart 2010; 96: 817-23.
35. Mathew S, Tustison KS, Sugatani T, et al,. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 2008; 19: 1092-105.
36. Tonelli M, Pannu N, Manns B,. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med. 2010; 362: 1312-24.
37. Block GA, Klassen PS, Lazarus JM, et al,. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004; 15: 2208-18. (Pubitemid 39031360)
38. Young EW, Albert JM, Satayathum S, et al,. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-87. (Pubitemid 41623345)
39. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al,. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-80. (Pubitemid 44215354)
40. Wald R, Sarnak MJ, Tighiouart H, et al,. Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am. J. Kidney Dis. 2008; 52: 531-40.
41. Tentori F, Blayney MJ, Albert JM, et al,. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2008; 52: 519-30.
42. Floege J, Kim J, Ireland E, et al,. Serum iPTH, calcium and phosphate, and the risk of mortality in a European heamodialysis population. Nephrol. Dial. Transplant. 2011; 26: 1948-55.
43. Sampaio MS, Molnar MZ, Kovesdy CP, et al,. Association of pretransplant serum phosphorus with posttransplant outcomes. Clin. J. Am. Soc. Nephrol. 2011; 6: 2712-21.
44. Roodnat JI, van Gurp EA, Mulder PG, et al,. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 2006; 82: 362-7. (Pubitemid 44223035)
45. Hruska K, Mathew S, Lund R, Fang Y, Sugatani T,. Cardiovascular risk factors in chronic kidney disease: Does phosphate qualify? Kidney Int. 2011; 79 (Suppl 121): S9-13.
46. Narang R, Ridout D, Nonis C, Kooner JS,. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int. J. Cardiol. 1997; 60: 73-9. (Pubitemid 27288259)
47. Verma A, Anavekar NS, Meris A, et al,. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: The VALIANT Echo Study. J. Am. Coll. Cardiol. 2007; 50: 1238-45. (Pubitemid 47405128)
48. Eckardt KU, Scherhag A, Macdougall IC, et al,. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J. Am. Soc. Nephrol. 2009; 20: 2651-60.
49. Patel RK, Oliver S, Mark PB, et al,. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin. J. Am. Soc. Nephrol. 2009; 4: 1477-83.
50. Boner G, Cooper ME, McCarroll K, et al,. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; 48: 1980-7. (Pubitemid 41416906)
51. Weiner DE, Tighiouart H, Vlagopoulos PT, et al,. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 1803-10. (Pubitemid 41716487)
52. London G, Guerin A, Marchais S, et al,. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003; 18: 1731-40. (Pubitemid 37098542)
53. Blacher J, Guerin AP, Pannier B, et al,. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-39. (Pubitemid 29218240)
54. Vlachopoulos C, Aznaouridis K, Stefanadis C,. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010; 55: 1318-27.
55. Ferro CJ, Chue CD, Steeds RP, Townend JN,. Is lowering phosphate exposure the key to preventing arterial stiffening with age? Heart 2009; 95: 1770-2.
56. Othmane TEH, Bakonyi G, Egresits J, et al,. Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: A prospective observational study. Hemodial. Int. 2007; 11: S13-21. (Pubitemid 47491286)
57. Takenaka T, Suzuki H,. New strategy to attenuate pulse wave velocity in haemodialysis patients. Nephrol. Dial. Transplant. 2005; 20: 811-16. (Pubitemid 40520661)
58. Mitsnefes MM, Kimball TR, Kartal J, et al,. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J. Am. Soc. Nephrol. 2005; 16: 2796-803.
59. Chiu Y-W, Adler SG, Budoff MJ, et al,. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010; 77: 1107-14.
60. Jono S, McKee MD, Murry CE, et al,. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000; 87: e10-7.
61. Kendrick J, Chonchol M,. The role of phosphorus in the development and progression of vascular calcification. Am. J. Kidney Dis. 2011; 58: 826-34.
62. Giachelli CM,. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J. Am. Soc. Nephrol. 2003; 14: 5300-4.
63. Li X, Yang HY, Giachelli CM,. Role of the sodium-dependent phosphate co-transporter Pit-1, in vascular smooth muscle cell calcification. Circ. Res. 2006; 98: 905-12.
64. Shigematsu T, Kono T, Satoh K, et al,. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol. Dial. Transplant. 2003; 18 (Suppl 3): iii86-9. (Pubitemid 36826936)
65. Goodman WG, Goldin J, Kuizon BD, et al,. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000; 342: 1478-83. (Pubitemid 30318271)
66. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG,. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol. Dial. Transplant. 2012; 27: 727-33.
67. McCullough PA, Sandberg KR, Dumler F, Yanez JE,. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J. Nephrol. 2004; 17: 205-15. (Pubitemid 38779772)
68. Neves KR, Graciolli FG, dos Reis LM, et al,. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004; 66: 2237-44. (Pubitemid 41115286)
69. Voormolen N, Noordzij M, Grootendorst DC, et al,. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol. Dial. Transplant. 2007; 22: 2909-16. (Pubitemid 350093423)
70. Norris KC, Greene T, Kopple J, et al,. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J. Am. Soc. Nephrol. 2006; 17: 2928-36. (Pubitemid 44484684)
71. Schwarz S, Trivedi BK, Kalantar-Zadeh K, et al,. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006; 1: 825-31.
72. Zoccali C, Ruggenenti P, Perna A, et al,. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J. Am. Soc. Nephrol. 2011; 22: 1923-30.
73. Shimada T, Hasegawa H, Yamazaki Y, et al,. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004; 19: 429-35. (Pubitemid 38787398)
74. Saito H, Kusano K, Kinosaki M, et al,. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J. Biol. Chem. 2003; 278: 2206-11. (Pubitemid 36801287)
75. Ix JH, Shlipak MG, Wassel CL, Whooley MA,. Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study. Nephrol. Dial. Transplant. 2010; 25: 993-7.
76. Shigematsu T, Kazama JJ, Yamashita T, et al,. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 2004; 44: 250-6. (Pubitemid 38962552)
77. Gutiérrez OM, Mannstadt M, Isakova T, et al,. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-92.
78. Gutiérrez O, Isakova T, Rhee E, et al,. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 2205-15. (Pubitemid 41716454)
79. Larsson T, Nisbeth U, Ljunggren O, et al,. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-9. (Pubitemid 37449564)
80. Razzaque MS, Lanske B,. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J. Endocrinol. 2007; 194: 1-10. (Pubitemid 47162881)
81. Craver L, Marco MP, Martínez I, et al,. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171-6. (Pubitemid 46523434)
82. Jean G, Terrat J-C, Vanel T, et al,. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 2792-6.
83. Parker BD, Schurgers LJ, Brandenburg VM, et al,. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann. Int. Med. 2010; 152: 640-8.
84. Kendrick J, Cheung AK, Kaufman JS, et al,. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 2011; 22: 1913-22.
85. Seiler S, Reichart B, Roth D, et al,. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant. 2010; 25: 3983-9.
86. Gutiérrez OM, Januzzi JL, Isakova T, et al,. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
87. Mirza MA, Larsson A, Melhus H, et al,. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-51.
88. Mirza MA, Hansen T, Johansson L, et al,. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant. 2009; 24: 3125-31.
89. Mirza MA, Larsson A, Lind L, Larsson T,. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-90.
90. Yilmaz MI, Sonmez A, Saglam M, et al,. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010; 78: 679-85.
91. Isakova T, Xie H, Yang W, et al,. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-9.
92. Fliser D, Kollerits B, Neyer U, et al,. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600-8.
93. Nasrallah MM, El-Shehaby AR, Salem MM, et al,. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 2010; 25: 2679-85.
94. Kanbay M, Nicoleta M, Selcoki Y, et al,. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 1780-6.
95. Desjardins L, Liabeuf S, Renard C, et al,. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos. Int. 2011 [Epub ahead of print].
96. Faul C, Amaral AP, Oskouei B, et al,. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011; 121: 4393-408.
97. Isakova T, Gutiérrez OM, Chang Y, et al,. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 2009; 20: 388-96.
98. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K,. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am. J. Kidney Dis. 2010; 56: 842-51.
99. Chertow GM, Burke SK, Raggi P,. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-52. (Pubitemid 34754068)
100. Russo D, Miranda I, Ruocco C, et al,. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007; 72: 1255-61. (Pubitemid 350059663)
101. Block GA, Spiegel DM, Ehrlich J, et al,. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-24. (Pubitemid 43169927)
102. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG,. Reduction of aortic calcification with lanthanum carbonate vs calcium-based phosphate binders in haemodialysis-A randomized controlled trial. Nephrology 2010; 16: 290-8.
103. Di Iorio B, Bellasi A, Russo D, et al,. Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin. J. Am. Soc. Nephrol. 2012; 7: 487-93.
104. Jamal SA, Fitchett D, Lok CE, et al,. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis. Nephrol. Dial. Transplant. 2009; 24: 3168-74.
105. Suki WN, Zabaneh R, Cangiano JL, et al,. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-7. (Pubitemid 47609037)
106. Block GA, Raggi P, Bellasi A, et al,. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-41.
107. The Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009; 113: S1-130.
108. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42 (Suppl 3): S1-201.
109. Elder G, Faull R, Branley P, et al,. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006; 11: S230-61.
110. National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians (UK), 2008. (NICE Clinical Guidelines, No. 73).
111. Isakova T, Gutiérrez OM, Smith K, et al,. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2011; 26: 584-91.
112. Oliveira RB, Cancela ALE, Graciolli FG, et al,. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 2010; 5: 286-91.
113. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, et al,. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol. Dial. Transplant. 2011; 26: 2567-71.
114. Yilmaz MI, Sonmez A, Saglam M, et al,. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am. J. Kidney Dis. 2012; 59: 177-85.
115. Antoniucci DM, Yamashita T, Portale AA,. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006; 91: 3144-9. (Pubitemid 44271770)
116. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS,. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 2006; 21: 1187-96. (Pubitemid 44128331)
117. Gutiérrez OM, Wolf M, Taylor EN,. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin. J. Am. Soc. Nephrol. 2011; 6: 2871-8.
118. Yamamoto KT, Robinson-Cohen C, de Oliveira MC, et al,. Dietary phosphorus is associated with left ventricular mass: The Multi-Ethnic Study of Atherosclerosis. American Society of Nephrology Kidney Week 2011, Oral Presentation SA-OR351, Philadelphia, PA.
119. Murtaugh MA, Filipowicz R, Baird BC, Wei G, Greene T, Beddhu S,. Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrol. Dial. Transplant. 2012; 27: 990-6.
120. Moe SM, Chen NX, Seifert MF, et al,. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009; 75: 176-84.
121. Moe SM, Zidehsarai MP, Chambers MA, et al,. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 257-64.
122. Sullivan C, Sayre SS, Leon JB, et al,. Effect of food additives on hyperphosphatemia among patients with endstage renal disease: A randomized controlled trial. JAMA 2009; 301: 629-35.
123. Isakova T, Wahl P, Vargas GS, et al,. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-8.
124. Wolf M,. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol. 2010; 21: 1427-35.
125. Block GA, Persky MS, Ketteler M, et al,. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. Hemodial. Int. 2009; 13: 360-2.
126. Chue CD, Townend JN, Steeds RP, Ferro CJ,. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: The CRIB-PHOS randomised controlled trial. Trials 2011; 12: 30.
127. Australian New Zealand Clinical Trials Registry website. ACTRN12610000650099. [Cited 23 May 2012.] Available from URL